Search Results
Your search for all items matches 34717 pages
Showing 13501 - 13550Extended Letrozole Boosts Disease-Free Survival in 10-Year Update of NSABP B-42 Trial
“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no significant improvement in overall survival with letrozole, but letrozole continued to provide a...
Expert Point of View: Michael Jain, MD, PhD
Michael Jain, MD, PhD, of the Moffitt Cancer Center, Tampa, Florida, commented on both studies with the combination of brentuximab vedotin/nivolumab. “For older patients, ABVD [doxorubicin, bleomycin, vinblastine, dacarbazine] is not easy to tolerate, and it would be good to find an easier...
Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma
The combination of brentuximab vedotin and nivolumab is making headway as first-line therapy for older adults with Hodgkin lymphoma and as salvage therapy for adults with relapsed or refractory classic Hodgkin lymphoma, according to separate studies presented at the 2019 Annual Meeting &...
Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?
Proton pump inhibitors, which are sometimes recommended to ease stomach problems during cancer treatment, may have an unintended side effect: impairment of breast cancer survivors' memory and concentration. These findings were published by Madison et al in the Journal of Cancer Survivorship....
Using T-Cell Fraction to Predict Melanoma Recurrence
In a paper published by Pruessmann et al in Nature Cancer, investigators presented a new, quantitative technique that leverages DNA sequencing to make more sophisticated and accurate predictions about which primary melanomas are likely to recur and spread. "As recently as 10 years ago, the outlook...
Immune-Related Adverse Events and Recurrence-Free Survival With Adjuvant Immunotherapy vs Placebo in Stage III Melanoma
In an analysis of the EORTC 1325/KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in stage III melanoma reported in JAMA Oncology, Alexander M.M. Eggermont, MD, PhD, and colleagues found that patients treated with pembrolizumab who experienced immune-related adverse events had improved...
Impact of the NCI Cell-Line Database: A Testament to Patient Altruism
In an homage to the gracious patients who provided biospecimens and to the dedicated researchers who have tended and studied the derived cell lines, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Internal Medicine, Rush University, and colleagues have described the impact of...
Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer
A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in patients with primary breast cancer, with a greater magnitude of benefit in patients with...
Cancer Incidence in World Trade Center Responders to the September 11 Attacks
A study published by Shapiro et al in JNCI Cancer Spectrum showed that responders to the World Trade Center site after the attacks on September 11, 2001, have statistically significant elevations in cancer incidence for all cancer sites combined, and for prostate and thyroid cancer and leukemia....
Three Studies Examine Relationship Between B-Cell Enrichment and Response to Immunotherapy
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures, according to three studies all recently published in Nature. The studies showed that enrichment of B cells...
Relapse and Outcomes in Men Receiving Adjuvant Bleomycin/Etoposide/Cisplatin for Clinical Stage I Nonseminoma
In a study reported in the Journal of Clinical Oncology, Fischer et al found different patterns of relapse and associated outcomes among men with relapse after treatment with adjuvant bleomycin/etoposide/cisplatin for clinical stage I nonseminoma. The study included data on 51 patients from 18...
Entrectinib in Advanced ROS1 Fusion–Positive NSCLC
As reported in The Lancet Oncology by Alexander Drilon, MD, and colleagues, an integrated analysis of three phase I/II trials has shown high activity of the TRK and ROS1 inhibitor entrectinib in ROS1 fusion-positive non–small cell lung cancer (NSCLC). This analysis supported the August 2019 U.S....
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
We’ll start off this week by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes. Then, we’ll move to a study that’s been covered a lot in the news: does the use of powder in the genital area increase a woman’s chance of ovarian...
Society for Integrative Oncology’s 16th International Conference
The Society for Integrative Oncology (SIO) hosted its 16th International Conference in New York City, October 19-21, 2019, in partnership with Memorial Sloan Kettering Cancer Center (MSK). The conference theme, “Advancing the Science and Art of Integrative Oncology,” focused on deepening the...
FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for ovarian, prostate, and lung cancer; granted Orphan Drug designation to therapies for chemotherapy-induced thrombocytopenia and multiple myeloma; and granted Breakthrough Device designation to platforms...
Treatment Resistance and Novel Therapies in FGFR-Mutated Cholangiocarcinoma
A new study has shown how resistance to fibroblast growth factor receptor (FGFR) inhibitor treatment develops in patients with cholangiocarcinoma and suggests that adding another therapy at the time of disease progression might resensitize tumor cells to initial therapy. These findings were...
External-Beam Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation After Breast-Conserving Surgery in DCIS or Node-Negative Breast Cancer
As reported in The Lancet by Timothy J. Whelan, BM, BCh, and colleagues, the phase III noninferiority RAPID trial has shown that external-beam accelerated partial-breast irradiation is noninferior to whole-breast irradiation in reducing risk of local recurrence after breast-conserving surgery in...
Conditioning Intensity for Allogeneic Transplantation in Patients With AML
In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...
Comparing Options for Ovarian Tissue Cryopreservation to Preserve Fertility in Pediatric Patients With Cancer
With the pediatric cancer survival rate exceeding 80%, “we can reasonably suspect that most of these children will survive more than 5 years from their diagnosis and then go on to puberty,” when they may have to deal with the consequences of cancer treatment, according to Rebecca Flyckt, MD,...
Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous NSCLC
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Seto et al found that the addition of maintenance pemetrexed to bevacizumab did not significantly improve overall survival in patients with previously untreated, advanced nonsquamous non–small cell lung cancer (NSCLC)...
Genomic Aberrations and Pancreatic Cancer Subtypes
Researchers have discovered detailed new genetic information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease, Chan-Seng-Yue et al reported in Nature Genetics. The study...
Are Women in Europe or Asia More Likely to Have Breast-Conserving Therapy Than Those in the United States?
Neoadjuvant systemic therapy can shrink tumors in patients with breast cancer and, in some cases, allow patients to receive breast-conserving therapy who would otherwise require mastectomy. However, in the United States, about 55% of patients who become eligible for breast-conserving therapy after...
Expert Point of View: Howard J. Weinstein, MD
Commenting on the blinatumomab study, Howard J. Weinstein, MD, Chief of Pediatric Hematology-Oncology at Massachusetts General Hospital for Children and Harvard Medical School in Boston, said: “These are very promising results for children, adolescents, and young adults who have had a first...
Selected Abstracts on Novel Therapies for Chronic Myeloid Leukemia
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for chronic myeloid leukemia (CML). For full details of...
Blinatumomab Outperforms Chemotherapy as Post-Reinduction Consolidation Therapy in Younger Patients With B-Cell ALL
Blinatumomab was superior to standard chemotherapy in children, adolescents, and young adults at the first relapse of B-cell acute lymphoblastic leukemia (ALL) as post-reinduction consolidation therapy prior to hematopoietic stem cell transplant (HSCT), according to the results of a late-breaking...
Cancer Survivors Face Substantial Medical Financial Hardship
Although advances in cancer treatments have led to huge increases in the number of survivors in the United States—more than 16.9 million in 2019—many of those survivors, particularly those aged 18 to 64, face substantial medical financial hardship due to their diagnosis and treatment, necessitating ...
Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
As reported in the Journal of Clinical Oncology by Tarhini et al, the phase III Intergroup E1609 trial has shown an overall survival advantage with adjuvant ipilimumab at 3 mg/kg—but not at 10 mg/kg—vs high-dose interferon alfa-2b in patients with resected high-risk cutaneous melanoma. The...
Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer
Researchers have developed a method based on artificial intelligence (AI) for the histopathologic diagnosis and grading of prostate cancer. The study, published by Ström et al in The Lancet Oncology, showed that the AI system can be trained to detect and grade prostate cancer from needle biopsy...
Higher 21-Gene Recurrence Score May Be Associated With Increased Risk of Locoregional Recurrence in Patients With Breast Cancer
A new study shows that a test physicians commonly use to guide chemotherapy for patients with breast cancer after surgery may also help them decide whether radiation therapy may be of benefit. Results published by Wendy A. Woodward, MD, PhD, and colleagues in JAMA Oncology suggest patients with an...
Selected Abstracts on New Therapies for Newly Diagnosed Multiple Myeloma
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens including the monoclonal antibody daratumumab in combination ...
Patients With HPV-Positive and HPV-Negative Oropharyngeal Cancer May Have Different Rates of Mortality
New research indicates that there is a higher risk of early death among patients with oropharyngeal cancer not associated with human papillomavirus (HPV) vs those whose tumors are HPV-positive. The findings are published by Fullerton et al in Cancer. The incidence of oropharyngeal cancer is...
Are Racial/Ethnic Disparities in Breast Cancer Diagnosis Caused by Health Insurance Coverage?
Lack of insurance coverage is a major cause of delayed breast cancer screening and treatment among minority women, which could lead to a decrease in a patient’s chance of survival. Nearly half of the disparity in later-stage diagnosis between non-Hispanic white women and black, Hispanic, and...
Patient-Reported Functional Outcomes With Hypofractionated vs Conventionally Fractionated Radiotherapy for Nonmetastatic Prostate Cancer
In a national cohort study conducted in the United Kingdom and reported in the Journal of Clinical Oncology, Nossiter et al found no clinically important differences in patient-reported functional outcomes among men receiving hypofractionated vs conventionally fractionated radiotherapy for...
Activity of Belantamab Mafodotin in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma
In the phase II DREAMM-2 trial reported in The Lancet Oncology, Sagar Lonial, MD, and colleagues found that the antibody-drug conjugate belantamab mafodotin was active in patients with heavily pretreated relapsed or refractory multiple myeloma. The agent is a conjugate of an anti–B-cell maturation...
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
In the phase III MEDALIST trial reported in The New England Journal of Medicine, Fenaux et al found that luspatercept significantly reduced the severity of anemia vs placebo in red blood cell transfusion–dependent patients with very low- to intermediate-risk myelodysplastic syndromes with ring...
Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Retrospective Analysis of PD-L1 Immunohistochemistry Assays
Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, discusses a retrospective analysis on the effectiveness of the VENTANA PD-L1 SP142 assay, the Dako 22C3 assay, and the VENTANA SP263 assay as predictors of response to atezolizumab plus nab-paclitaxel in...
ADMIRAL Trial: Gilteritinib Improves Overall Survival in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Alexander E. Perl, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage...
Molecular Characteristics of Leptomeningeal Melanoma Metastases
Patients with advanced melanoma who develop metastases in the leptomeninges usually have a poor prognosis—most patients only survive for 8 to 10 weeks after diagnosis. One reason for this poor prognosis is that very little is known about the molecular development of leptomeningeal melanoma...
Association Between Colorectal Cancer and Ulcerative Colitis
Patients with the inflammatory bowel disease ulcerative colitis have a higher risk of dying from colorectal cancer, despite modern therapy, even though the risk has declined in recent years. Olén et al published these findings in The Lancet. Previous research has shown that patients with ulcerative ...
Entrectinib in Advanced or Metastatic NTRK Fusion–Positive Solid Tumors
As reported in The Lancet Oncology by George D. Demetri, MD, and colleagues, integrated analysis of three phase I/II trials has shown high levels of activity of the tropomyosin receptor kinase (TRK) inhibitor entrectinib in advanced NTRK fusion–positive solid tumors. This analysis supported the...
Activity of Ruxolitinib in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
In a phase II study reported in the Journal of Clinical Oncology, Dao et al found that the JAK1/2 inhibitor ruxolitinib was active in patients with chronic neutrophilic leukemia (CNL), with less activity observed in those with atypical chronic myeloid leukemia (CML) and greater activity observed...
Is There an Association Between Powder Use and Risk of Ovarian Cancer?
As reported in JAMA by O’Brien et al, pooled data from four large U.S.-based prospective cohorts suggest the lack of a significant association between the use of powder in the genital area and an increased risk of ovarian cancer. The investigators noted that the analysis may have not been...
Recent Approvals From the FDA
The U.S. Food and Drug Administration (FDA) certainly had a busy December, and this week, we’ll be reviewing some recent approvals: olaparib for germline BRCA-mutated metastatic pancreatic cancer; fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive breast...
Transplantation Specialist Karen Ballen, MD, Treasures Long-Term Connections With Her Patients
Karen Ballen, MD, an international expert in stem cell transplantation, particularly for patients who have a difficult time finding a donor, was born and reared in the Bronx in a family that encouraged academic and professional pursuits. “My grandfather was an old-fashioned pediatrician who made...
Patient Access to High-Quality Oncologic Pathology Improves Care
Accurate and timely diagnoses are critical components for developing treatment plans for patients with cancer and also for informing prognosis and assessment of responses. Pathologists are an essential part of the oncology team because they have specialized knowledge that helps inform diagnostic...
FDA Pipeline: Fast Track/Orphan Drug Designation for Cholangiocarcinoma Treatment, Breakthrough Device Designation for Bladder Cancer Test
This week, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to infigratinib for patients with advanced or metastatic cholangiocarcinoma with a certain genetic mutation, and Orphan Drug designation to the treatment for patients with cholangiocarcinoma. The FDA also granted...
Does Statin Use Increase Overall Survival in Patients With Colorectal Cancer?
About 40 million adults in the United States take a statin to lower their cholesterol and reduce the risk for heart disease—but they may also be getting an added anticancer benefit, a growing body of evidence suggests. According to research presented at the American Heart Association’s Scientific...
Does Adding Trastuzumab to Adjuvant Chemotherapy Improve Invasive Disease–Free Survival for Patients With HER2-Negative Breast Cancer?
As reported in the Journal of Clinical Oncology by Louis Fehrenbacher, MD, and colleagues, the phase III NSABP B-47/NRG Oncology trial has shown no invasive disease–free survival benefit with the addition of trastuzumab to adjuvant chemotherapy therapy in patients with HER2-negative breast cancer...
FDA Approves Avapritinib for the Treatment of PDGFRA-Mutated Gastrointestinal Stromal Tumor
On January 9, the U.S. Food and Drug Administration (FDA) approved avapritinib (Ayvakit) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) that harbors platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. This approval includes...
Expert Point of View: Gary Schiller, MD
At the press conference where these data were presented, moderator Gary Schiller, MD, of the University of California, Los Angeles, explained that although chimeric antigen receptor (CAR) T-cell therapy is a major advance in cellular immunotherapy, enabling killing of cancer cells in blood and bone ...
